Inogen, Inc., a medical technology company, primarily develops, manufactures, and markets portable oxygen concentrators for patients, physicians and other clinicians, and third-party payors in the United States and internationally. The company's oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. It offers Inogen One, a portable device that concentrate the air around the patient to provide a single source of supplemental oxygen; and Inogen At Home stationary oxygen concentrators, as well as related accessories. The company also rents its products directly to patients. Inogen, Inc. was founded in 2001 and is headquartered in Goleta, California.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Surgical appliances & supplies
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:INGN
CUSIPN/A
Phone805-562-0500
Debt
Debt-to-Equity RatioN/A
Current Ratio6.67
Quick Ratio6.06
Price-To-Earnings
Trailing P/E Ratio160.09
Forward P/E Ratio118.49
P/E Growth5.37
Sales & Book Value
Annual Sales$249.44 million
Price / Sales17.84
Cash Flow$1.9242 per share
Price / Cash108.99
Book Value$10.88 per share
Price / Book19.28
Profitability
EPS (Most Recent Fiscal Year)$1.31
Net Income$21 million
Net Margins9.36%
Return on Equity14.81%
Return on Assets12.19%
Miscellaneous
Employees770
Outstanding Shares21,220,000
Market Cap$4,530.37
Inogen (NASDAQ:INGN) Frequently Asked Questions
What is Inogen's stock symbol?
Inogen trades on the NASDAQ under the ticker symbol "INGN."
How were Inogen's earnings last quarter?
Inogen Inc (NASDAQ:INGN) released its quarterly earnings results on Monday, April, 30th. The medical technology company reported $0.48 EPS for the quarter, beating the Thomson Reuters' consensus estimate of $0.29 by $0.19. The medical technology company had revenue of $79.05 million for the quarter, compared to analysts' expectations of $63.86 million. Inogen had a net margin of 9.36% and a return on equity of 14.81%. Inogen's revenue was up 50.6% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.27 earnings per share. View Inogen's Earnings History.
What price target have analysts set for INGN?
5 brokerages have issued twelve-month price targets for Inogen's stock. Their forecasts range from $170.00 to $235.00. On average, they anticipate Inogen's share price to reach $200.00 in the next twelve months. This suggests that the stock has a possible downside of 4.6%. View Analyst Ratings for Inogen.
What is the consensus analysts' recommendation for Inogen?
5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Inogen in the last year. There are currently 1 hold rating and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
What are Wall Street analysts saying about Inogen stock?
Here are some recent quotes from research analysts about Inogen stock:
- 1. According to Zacks Investment Research, "Inogen outperformed its industry in the past year. Solid growth in business-to-business and direct-to-consumer segments are major positives. Strong sales in the United States and Europe also raise optimism. A raised guidance for 2018 paints a bright picture. Lately, the company has invested in research and development, which is encouraging as well. An expanding Long-term Oxygen Therapy (LTOT) market, inherent benefits of POCs over traditional delivery model, underpenetrated international markets and expanding product portfolio also deserve a mention. On the flip side, declining operating margins owing to surging R&D expenses raise concern. The decline in rental revenues adds to the woes. Additionally, management expects rental revenues to decline around 10% in 2018 from 2017. Stiff competition in the niche space is likely to mar prospects." (7/11/2018)
- 2. Needham & Company LLC analysts commented, "We hosted for management meetings in Boston and Toronto last week. Recent sales and marketing investments (CRM, training, and new hires) are paying off with higher growth. We think INGN’s DTC channel is a competitive advantage and one that is difficult for competitors to copy. INGN is increasingly spending its R&D dollars on research as opposed to development; we expect it to launch the G5 next year. The US POC market remains significantly underpenetrated and international markets, particularly emerging markets, have minimal penetration. Despite facing some much larger competitors, we believe INGN has the best POCs and that it can maintain its lead. We expect INGN to sustain very strong revenue growth for the next few years and to continue to deliver upside to consensus estimates and we reiterate our Strong Buy rating." (6/13/2018)
Who are some of Inogen's key competitors?
Some companies that are related to Inogen include Smith & Nephew (SNN), WILLIAM DEMANT/ADR (WILYY), Steris (STE), MSA Safety (MSA), Halyard Health (HYH), Wright Medical Group (WMGI), CONSORT Med PLC/S (CSRMY), Invacare (IVC), Sientra (SIEN), RTI Surgical (RTIX), Lakeland Industries (LAKE), Histogenics (HSGX), ConforMIS (CFMS), Rewalk Robotics (RWLK) and COLLPLANT HOLDI/S (CLGN).
Who are Inogen's key executives?
Inogen's management team includes the folowing people:
- Mr. Scott Wilkinson, CEO, Pres & Director (Age 53)
- Mr. Brenton Taylor, Exec. VP of Engineering (Age 37)
- Ms. Alison Perry Bauerlein, Exec. VP of Fin., CFO, Corp. Sec. & Treasurer (Age 37)
- Mr. Matthew S. Scribner, Exec. VP of Operations (Age 51)
- Mr. Byron Myers, Exec. VP of Sales & Marketing (Age 39)
Has Inogen been receiving favorable news coverage?
Media stories about INGN stock have trended somewhat positive on Sunday, according to Accern Sentiment Analysis. The research firm ranks the sentiment of press coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Inogen earned a media sentiment score of 0.17 on Accern's scale. They also assigned news coverage about the medical technology company an impact score of 46.44 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company's share price in the next few days.
Who are Inogen's major shareholders?
Inogen's stock is owned by many different of retail and institutional investors. Top institutional shareholders include Fred Alger Management Inc. (1.47%), Peregrine Capital Management LLC (0.92%), Chicago Capital LLC (0.59%), Foundry Partners LLC (0.11%), Mitsubishi UFJ Asset Management UK Ltd. (0.10%) and Curbstone Financial Management Corp (0.08%). Company insiders that own Inogen stock include Alison Bauerlein, Brenton Taylor, Byron Myers, Heath Lukatch, Heather D Rider, Loren L Mcfarland, Matt Scribner, Ray Benjamin M Anderson, Raymond Huggenberger and Scott Wilkinson. View Institutional Ownership Trends for Inogen.
Which institutional investors are selling Inogen stock?
INGN stock was sold by a variety of institutional investors in the last quarter, including Peregrine Capital Management LLC, Curbstone Financial Management Corp, Municipal Employees Retirement System of Michigan, Foundry Partners LLC, Bank of Montreal Can and Empowered Funds LLC. Company insiders that have sold Inogen company stock in the last year include Alison Bauerlein, Brenton Taylor, Byron Myers, Heath Lukatch, Heather D Rider, Loren L Mcfarland, Matt Scribner, Ray Benjamin M Anderson, Raymond Huggenberger and Scott Wilkinson. View Insider Buying and Selling for Inogen.
Which institutional investors are buying Inogen stock?
INGN stock was purchased by a variety of institutional investors in the last quarter, including Fred Alger Management Inc., Mitsubishi UFJ Asset Management UK Ltd., Chicago Capital LLC, Amalgamated Bank and Xact Kapitalforvaltning AB. View Insider Buying and Selling for Inogen.
How do I buy shares of Inogen?
Shares of INGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Inogen's stock price today?
One share of INGN stock can currently be purchased for approximately $209.72.
How big of a company is Inogen?
Inogen has a market capitalization of $4.53 billion and generates $249.44 million in revenue each year. The medical technology company earns $21 million in net income (profit) each year or $1.31 on an earnings per share basis. Inogen employs 770 workers across the globe.
How can I contact Inogen?
Inogen's mailing address is 326 BOLLAY DRIVE, GOLETA CA, 93117. The medical technology company can be reached via phone at 805-562-0500 or via email at [email protected]
MarketBeat Community Rating for Inogen (NASDAQ INGN)
MarketBeat's community ratings are surveys of what our community members think about Inogen and other stocks. Vote "Outperform" if you believe INGN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe INGN will underperform the S&P 500 over the long term. You may vote once every thirty days.
